Navjot Kaur
Research Subjects
Navjot Kaur has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Rahul Kumar Sharma
Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Department of Pharmacology, Bela, Punjab, India
2 shared publications - Simrandeep Singh
Department of Electronics and Communication Engineering, University Institute of Engineering (UIE), Chandigarh University, Gharuan, Mohali 140413, Punjab, India
2 shared publications - Aanchal Verma
Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Department of Pharmacology, Bela, Ropar, Punjab, India
1 shared publication Anita Gehlot
Uttaranchal Institute of Technology, Uttaranchal University, Dehradun, India
1 shared publication- Navreet Kaur
Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Department of Pharmacology, Bela, Ropar, Punjab, India
1 shared publication - Satnam Singh
Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, An Autonomous college, Bela, Ropar, Punjab, India
1 shared publication
Latest Publications
- 22 October 2026
- Published by Taylor & Francis
- p. 161-187
Valorization of Fruit Waste as Biofertilizer and Biopesticide
The conversion of fruit waste (FW) into biofertilizers and biopesticides, thereby offering a way of managing agricultural and food industry waste and at the same time contributing to green agriculture. Fruits and their wastes contain nutrients, organic matters, and bioactive compounds that are important for the production of microbial biofertilizers and natural pest repellents. This transformation is not only a way to redeem the fertility of the soil and health of the plants but also a way to decrease the intensive usage of chemicals that have negative influence on the environment and human health. Some of the techniques used include composting, anaerobic digestion, fermentation, and green extraction techniques to recycle the above wastes into agriculturally useful products. More recent incorporations suggest the ideal use of bioformulations produced from FW in farming systems, backed up by concepts on cost implications and the possibility of scale-up in industrial-level examples. The economic feasibility or advantage of this approach lies in the low cost of raw material and the added value from waste product. Though some concerns are still there, such as fluctuation in the waste generation frequency throughout the year, the lack of standardization, the limitation of the laws, and problems arising from the microbial stability and shelf life of the final product. To overcome all these limitations, future directions are given toward high biotechnological events, advanced implements of precision agriculture, and generation of combined multipurpose formulations of biofertilizers and biopesticides. To improve the commercialization and increase the societal acceptance of such products, the use of circular economy principles and increased collaboration between government and companies is encouraged. In conclusion, utilizing FW as biofertilizers and biopesticides remains a strong and sustainable solution for regenerative agriculture.
- 22 October 2026
- Published by Taylor & Francis
- p. 161-187
Valorization of Fruit Waste as Biofertilizer and Biopesticide
The conversion of fruit waste (FW) into biofertilizers and biopesticides, thereby offering a way of managing agricultural and food industry waste and at the same time contributing to green agriculture. Fruits and their wastes contain nutrients, organic matters, and bioactive compounds that are important for the production of microbial biofertilizers and natural pest repellents. This transformation is not only a way to redeem the fertility of the soil and health of the plants but also a way to decrease the intensive usage of chemicals that have negative influence on the environment and human health. Some of the techniques used include composting, anaerobic digestion, fermentation, and green extraction techniques to recycle the above wastes into agriculturally useful products. More recent incorporations suggest the ideal use of bioformulations produced from FW in farming systems, backed up by concepts on cost implications and the possibility of scale-up in industrial-level examples. The economic feasibility or advantage of this approach lies in the low cost of raw material and the added value from waste product. Though some concerns are still there, such as fluctuation in the waste generation frequency throughout the year, the lack of standardization, the limitation of the laws, and problems arising from the microbial stability and shelf life of the final product. To overcome all these limitations, future directions are given toward high biotechnological events, advanced implements of precision agriculture, and generation of combined multipurpose formulations of biofertilizers and biopesticides. To improve the commercialization and increase the societal acceptance of such products, the use of circular economy principles and increased collaboration between government and companies is encouraged. In conclusion, utilizing FW as biofertilizers and biopesticides remains a strong and sustainable solution for regenerative agriculture.
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 57 (3) , 661-674
Gut microbiome and diabetes: Emerging perspectives in metabolic regulation
Diabetes mellitus type 2 (T2DM) is one of the fastest-growing metabolic disorders in the world. It is marked by insulin resistance, high blood sugar and high cholesterol levels. Recently, its prevalence has increased significantly, making it a major health issue globally. New evidence shows that people with T2DM often have changes in their gut microbiota composition and suffer from problems in multiple organ systems. This review focused on the changes in gut microbiota related to T2DM and examined how microbial byproducts affect the disease's development. The potential for identifying at-risk individuals based on microbial patterns and the creation of specific treatments was also discussed. Lastly, it was looked into gut health strategies that aim to change the gut microbiota to prevent or slow the advancement of T2DM.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 57 (3) , 661-674
Open AccessGut microbiome and diabetes: Emerging perspectives in metabolic regulation
Diabetes mellitus type 2 (T2DM) is one of the fastest-growing metabolic disorders in the world. It is marked by insulin resistance, high blood sugar and high cholesterol levels. Recently, its prevalence has increased significantly, making it a major health issue globally. New evidence shows that people with T2DM often have changes in their gut microbiota composition and suffer from problems in multiple organ systems. This review focused on the changes in gut microbiota related to T2DM and examined how microbial byproducts affect the disease's development. The potential for identifying at-risk individuals based on microbial patterns and the creation of specific treatments was also discussed. Lastly, it was looked into gut health strategies that aim to change the gut microbiota to prevent or slow the advancement of T2DM.
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 57 (3) , 631-646
Antifungal pharmacotherapy and hepatic safety: Mechanisms of drug-induced liver injury (DILI) and risk mitigation
The growing prevalence of invasive fungal infections (IFIs), especially among immunocompromised patients, has resulted in increased reliance on systemic antifungal therapies. Hepatotoxicity is still a serious clinical problem even with improvements in treatment results. This study consolidates the mechanisms, incidence rates and risk factors associated with drug-induced liver injury (DILI) across various antifungal classes, including flucytosine, azoles, polyenes, echinocandins and allylamines. Triazole antifungals, such as voriconazole, fluconazole and ketoconazole are particularly implicated because of their substantial hepatic metabolism via cytochrome P450 enzymes and potential for interactions between drugs. Direct hepatocyte damage, immune-mediated responses, mitochondrial malfunction and changes in cytokine signalling are some of the mechanisms of hepatotoxicity. Terbinafine and other echinocandins and allylamines can also be hepatotoxic, particularly when combined with polypharmacy and pre-existing liver illness. Acute liver failure and asymptomatic liver enzyme increases are examples of clinical symptoms. To maximise treatment while reducing hepatic side effects, a thorough understanding of antifungal pharmacokinetics, metabolism and patient-related risk factors is necessary.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in SCRIPTA MEDICA
- Vol. 57 (3) , 631-646
Open AccessAntifungal pharmacotherapy and hepatic safety: Mechanisms of drug-induced liver injury (DILI) and risk mitigation
The growing prevalence of invasive fungal infections (IFIs), especially among immunocompromised patients, has resulted in increased reliance on systemic antifungal therapies. Hepatotoxicity is still a serious clinical problem even with improvements in treatment results. This study consolidates the mechanisms, incidence rates and risk factors associated with drug-induced liver injury (DILI) across various antifungal classes, including flucytosine, azoles, polyenes, echinocandins and allylamines. Triazole antifungals, such as voriconazole, fluconazole and ketoconazole are particularly implicated because of their substantial hepatic metabolism via cytochrome P450 enzymes and potential for interactions between drugs. Direct hepatocyte damage, immune-mediated responses, mitochondrial malfunction and changes in cytokine signalling are some of the mechanisms of hepatotoxicity. Terbinafine and other echinocandins and allylamines can also be hepatotoxic, particularly when combined with polypharmacy and pre-existing liver illness. Acute liver failure and asymptomatic liver enzyme increases are examples of clinical symptoms. To maximise treatment while reducing hepatic side effects, a thorough understanding of antifungal pharmacokinetics, metabolism and patient-related risk factors is necessary.
- 10 July 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 179, 108810
Application of artificial intelligence in drug design: A review
- 10 July 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 179, 108810
Application of artificial intelligence in drug design: A review